<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345137</url>
  </required_header>
  <id_info>
    <org_study_id>MED.RES.HOS.1995.02.JNB</org_study_id>
    <nct_id>NCT00345137</nct_id>
  </id_info>
  <brief_title>Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis</brief_title>
  <official_title>Phase 1 Study of Systemic Effects of Ng-Monomethyl-L-Arginine on Renal Hemodynamics in Patients With Polycystic Kidney Disease and Chronic Glomerulonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regional Hospital Holstebro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regional Hospital Holstebro</source>
  <brief_summary>
    <textblock>
      The study tests the hypothesis that systemic and renal nitric oxide availability is changed&#xD;
      in polycystic kidney disease and chronic glomerulonephritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized, placebo controlled design, the effects of systemic treatment with&#xD;
      monomethyl-L-arginine are studied on:&#xD;
&#xD;
        1. renal hemodynamics&#xD;
&#xD;
        2. renal sodium excretion and lithium clearance&#xD;
&#xD;
        3. blood pressure and heart rate&#xD;
&#xD;
        4. plasma levels of vasoactive hormones&#xD;
&#xD;
      in patients with adult polycystic kidney disease and chronic glomerulonephrits. The results&#xD;
      are compared with a group of healthy control subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <enrollment>75</enrollment>
  <condition>ADPKD</condition>
  <condition>Glomerulonephritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ng-monomethyl-L-arginine (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  Age 20 to 60 years&#xD;
&#xD;
          -  Both men and women&#xD;
&#xD;
          -  Weight below 100 kg&#xD;
&#xD;
          -  Normal clinical examination and laboratory screening&#xD;
&#xD;
          -  Fertile women only if using contraception&#xD;
&#xD;
          -  Informed consent according to the regulations of the local etics committee&#xD;
&#xD;
        Chronic glomerulonephritis&#xD;
&#xD;
          -  Biopsy veryfied chronic glomerulonephritis&#xD;
&#xD;
          -  P-creatinine &lt; 250 µmol/L&#xD;
&#xD;
          -  Weight below 100 kg&#xD;
&#xD;
          -  Age 20 to 60 years&#xD;
&#xD;
          -  Both men and women&#xD;
&#xD;
          -  Informed consent according to the regulations of the local etics committee&#xD;
&#xD;
        Adult polycystic kidney disease (APKD)&#xD;
&#xD;
          -  Diagnosis of APKD by family history and renal ultrasound or renal angiography&#xD;
&#xD;
          -  P-creatinine &lt; 250 µmol/L&#xD;
&#xD;
          -  Weight below 100 kg&#xD;
&#xD;
          -  Age 20 to 60 years&#xD;
&#xD;
          -  Both men and women&#xD;
&#xD;
          -  Informed consent according to the regulations of the local etics committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy controls&#xD;
&#xD;
          -  History or clinical evidence of diseases of the heart and blood vessels, kidneys,&#xD;
             liver and pancreas, endocrine organs, lungs, neoplastic disease, myocardial infarction&#xD;
             or cerebrovascular insult as evaluated by clinical examination and laboratory&#xD;
             screening&#xD;
&#xD;
          -  Current medication&#xD;
&#xD;
          -  Drugs or alcohol abuse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previously within one year received more than 0.2 mSV radioactive treatment or&#xD;
             diagnostic substances&#xD;
&#xD;
          -  Donation of blood less than 1 month before the experiments&#xD;
&#xD;
        Chronic glomerulonephritis&#xD;
&#xD;
          -  Apart from chronic glomerulonephritis and hypertension no history of diseases of the&#xD;
             heart and blood vessels, liver and pancreas, endocrine organs, lungs, myocardial&#xD;
             infarction, cerebrovascular insult or neoplastic disease.&#xD;
&#xD;
          -  Patients with nephrotic syndrome or secondary glomerulonephritis&#xD;
&#xD;
          -  Current medication other than antihypertensive therapy&#xD;
&#xD;
          -  Drugs or alcohol abuse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previously within one year received more than 0.2 mSV radioactive treatment or&#xD;
             diagnostic substances&#xD;
&#xD;
        Adult polycystic kidney disease&#xD;
&#xD;
          -  Apart from APKD and hypertension no history of diseases of the heart and blood&#xD;
             vessels, liver and pancreas, endocrine organs, lungs, myocardial infarction,&#xD;
             cerebrovascular insult or neoplastic disease.&#xD;
&#xD;
          -  Current medication other than antihypertensive therapy&#xD;
&#xD;
          -  Drugs or alcohol abuse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previously within one year received more than 0.2 mSV radioactive treatment or&#xD;
             diagnostic substances&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erling B Pedersen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesper N Bech, MD, Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark</affiliation>
  </overall_official>
  <verification_date>June 2006</verification_date>
  <study_first_submitted>June 24, 2006</study_first_submitted>
  <study_first_submitted_qc>June 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2006</study_first_posted>
  <last_update_submitted>June 24, 2006</last_update_submitted>
  <last_update_submitted_qc>June 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2006</last_update_posted>
  <keyword>Renal hemodynamics</keyword>
  <keyword>Nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>omega-N-Methylarginine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

